4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Cash from Operations of 68125000.0 for Q1 2026, down 42.65% year-over-year from 118780393.19 in Q1 2025, and down 338.61% quarter-over-quarter from 28551000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Cash from Operations for 7 consecutive years, with 68125000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 42.65% year-over-year to 68125000.0; the TTM figure through Mar 2026 stood at 129449000.0 (up 15.53% YoY), while the FY2025 annual figure was 109082000.0, up 18.95% from the prior year.
- Cash from Operations declined to 68125000.0 in Q1 2026 per FDMT's latest filing, from 28551000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 28551000.0 in Q4 2025 and bottomed at 68125000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 27898176.47 across 5 years, with a median of 27906000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations slumped 2409.91% — and 2025, when it surged 162.25%.
- 4D Molecular Therapeutics' Cash from Operations stood at 22214000.0 in 2022, then declined by 10.97% to 24650000.0 in 2023, then plunged by 86.06% to 45863000.0 in 2024, then soared by 162.25% to 28551000.0 in 2025, then tumbled by 338.61% to 68125000.0 in 2026.
- Business Quant data shows FDMT's Cash from Operations at 68125000.0 in Q1 2026, 28551000.0 in Q4 2025, and 46498000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -70.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.00 Mn |
| Jun 30, 2026 | -70.00 Mn |
| Mar 31, 2026 | -68.13 Mn |
| Mar 31, 2026 | -68.13 Mn |
| Dec 31, 2025 | 28.55 Mn |
| Dec 31, 2025 | 28.55 Mn |
| Sep 30, 2025 | -46.50 Mn |
| Sep 30, 2025 | -46.50 Mn |
| Jun 30, 2025 | -43.38 Mn |
| Jun 30, 2025 | -43.38 Mn |
| Mar 31, 2025 | -47.76 Mn |
| Mar 31, 2025 | -47.76 Mn |
| Dec 31, 2024 | -45.86 Mn |
| Dec 31, 2024 | -45.86 Mn |
| Sep 30, 2024 | -29.39 Mn |
| Sep 30, 2024 | -29.39 Mn |
| Jun 30, 2024 | -30.24 Mn |
| Jun 30, 2024 | -30.24 Mn |
| Mar 31, 2024 | -29.09 Mn |
| Mar 31, 2024 | -29.09 Mn |